RxDoctor Payments Data

Timothy Gatz, MD

Family Medicine · Kalamazoo, MINPI 1689780231

Payments from drug & device makers

$2,160in general payments, 2019–2025

Across 103 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$413
  • Abbott$217
  • AstraZeneca$203
  • AbbVie$188
  • Boehringer Ingelheim$185
  • GSK$169
  • plus $786 from 13 others

What the payments were for

  • Food & beverage$2,160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,160 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$69,796
Medicare patients
303
Services billed
797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$183,645
TrulicityDulaglutide90$115,356
MounjaroTirzepatide77$104,076
OzempicSemaglutide76$87,531
JardianceEmpagliflozin55$63,937
XareltoRivaroxaban50$62,767
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$60,300
FarxigaDapagliflozin Propanediol53$48,119
Combivent RespimatIpratropium/Albuterol Sulfate46$24,663
JanuviaSitagliptin Phosphate19$24,006
LunestaEszopiclone13$12,891
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$11,257
MyrbetriqMirabegron12$10,625
Tresiba Flextouch U-200Insulin Degludec14$10,564
Atorvastatin Calcium625$10,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$167$219,432167 claims
PfizerEliquis$154$183,645180 claims
Boehringer IngelheimJardiance, Combivent Respimat$185$88,601101 claims
Novo NordiskOzempic$413$87,53176 claims
GSKTrelegy Ellipta, Breo Ellipta$169$64,952102 claims
AstraZenecaFarxiga$203$48,11953 claims
MerckJanuvia$116$24,00619 claims
AbbVieSynthroid$188$3,91240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →